Stocks Down Under Videos
Get a 3-month FREE TRIAL to CONCIERGE now!
Concierge gives you timely BUY and SELL alerts on ASX-listed stocks
Dimerix (ASX:DXB) is waiting for FDA feedback on its pivotal ACTION-3 study!
February 26, 2026
DXB, Dimerix
Dimerix (ASX:DXB)
We spoke to Dr Nina Webster, CEO of Dimerix (ASX:DXB), about the next steps for the company’s pivotal ACTION-3 study in Focal Segmental Glomerulosclerosis. The company is awaiting important feedback from the FDA, after which the study can be properly powered, if necessary, and then unblinded.
Check out the latest research on DXB by Pitt Street Research!
Looking for the Best ASX Life Sciences stocks to invest in right now?
